hat
Johnny Mahlangu, BSc, MBBCh, Mesye, FCPath te kenbe pozisyon lidèchip ak ISTH ak WFH. Li te sèvi nan biwo pale yo pou Alnylam, Bayer, Biotest, Biogen, ISTH, Novo Nordisk, Pfizer, Sobi, Shire, Roche, ak WFH. Dr. Mahlangu te resevwa finansman rechèch nan Alnylam, Bayer, Biotest, Biogen, ISTH, Novo Nordisk, Pfizer, Sobi, Shire, Roche, ak WFH. Li te resevwa onorè nan men Amgen, Bayer, Biotest, Biogen, Baxalta, CSL-Behring, Catalyst Biosciences, Chugai, Freeline, LFB, Novo Nordisk, Roche ak Spark.
eng
Johnny Mahlangu, BSc, MBBCh, MMed, FCPath has held leadership positions with ISTH and WFH. He has served on the speakers’ bureau for Alnylam, Bayer, Biotest, Biogen, ISTH, Novo Nordisk, Pfizer, Sobi, Shire, Roche, and WFH. Dr. Mahlangu has received research funding from Alnylam, Bayer, Biotest, Biogen, ISTH, Novo Nordisk, Pfizer, Sobi, Shire, Roche, and WFH. He has received honoraria from Amgen, Bayer, Biotest, Biogen, Baxalta, CSL- Behring, Catalyst Biosciences, Chugai, Freeline, LFB, Novo Nordisk, Roche, and Spark.